Mission
Breaking grounds as a nuclear medicine specialist
UZ Leuven pursues absolute leadership in its three key areas: patient care, training and research.
We play a leading role both in Belgium and throughout Europe and seek to maintain and develop this in the future. Every day more than 9,000 committed staff contribute all their skills to achieve that goal. UZ Leuven was the first hospital in Belgium to receive the international JCI label for safety and quality of care and is now centrally involved in establishing new national quality guidelines.
How will you break grounds?
UZ Leuven is the largest hospital in Belgium, located about 20 km east of Brussels, with 1,800 beds.
The department of nuclear medicine has a high clinical activity in all major domains and has over 35 years of PET experience. The department has a state-of-the-art multimodal infrastructure including 2 PET-CT cameras, Europe’s first ultra-high resolution NeuroExplorer PET-CT, 3 SPECT-CT cameras and a dedicated solid-state CZT camera. The radiopharmacy lab is fully GMP qualified with in-house cyclotron (IBA 18/9) and large synthesis capacity (18 vaults, 70 GMP radiotracers), with a second cyclotron, GMP and R&D facility in building phase. We offer a wide range of clinical diagnostic investigations, routinely including multiple non-FDG ligands. Several novel forms of radionuclide therapy (RNT) are carried out under own nuclear medicine governance and an extension to 10 RNT rooms is ready in 2027. An established quality management system is in place (ISO 9001:2018 based). The department also has a strong research program with spearpoints in brain imaging, oncology and inflammation imaging, including translational tracer development and imaging biomarkers for drug development. A strong medical physics team investigates image reconstruction, AI, dosimetry for RNT and advanced data processing. A fully equipped preclinical research unit with 2 microPET-CT and microSPECT-CT is available. All activities are performed by a motivated and dynamic team of MD’s, radiopharmacists, chemists, physicists, engineers and technologists. The approved nuclear medicine department’s policy plan for the next five years of the division explicitly includes expansion of clinical/innovative applications of the NeuroExplorer, radiotheranostics and PET/RNT radiotracer production.
UZ Leuven pursues absolute leadership in its three key areas: patient care, training and research.
We play a leading role both in Belgium and throughout Europe and seek to maintain and develop this in the future. Every day more than 9,000 committed staff contribute all their skills to achieve that goal. UZ Leuven was the first hospital in Belgium to receive the international JCI label for safety and quality of care and is now centrally involved in establishing new national quality guidelines.
How will you break grounds?
UZ Leuven is the largest hospital in Belgium, located about 20 km east of Brussels, with 1,800 beds.
The department of nuclear medicine has a high clinical activity in all major domains and has over 35 years of PET experience. The department has a state-of-the-art multimodal infrastructure including 2 PET-CT cameras, Europe’s first ultra-high resolution NeuroExplorer PET-CT, 3 SPECT-CT cameras and a dedicated solid-state CZT camera. The radiopharmacy lab is fully GMP qualified with in-house cyclotron (IBA 18/9) and large synthesis capacity (18 vaults, 70 GMP radiotracers), with a second cyclotron, GMP and R&D facility in building phase. We offer a wide range of clinical diagnostic investigations, routinely including multiple non-FDG ligands. Several novel forms of radionuclide therapy (RNT) are carried out under own nuclear medicine governance and an extension to 10 RNT rooms is ready in 2027. An established quality management system is in place (ISO 9001:2018 based). The department also has a strong research program with spearpoints in brain imaging, oncology and inflammation imaging, including translational tracer development and imaging biomarkers for drug development. A strong medical physics team investigates image reconstruction, AI, dosimetry for RNT and advanced data processing. A fully equipped preclinical research unit with 2 microPET-CT and microSPECT-CT is available. All activities are performed by a motivated and dynamic team of MD’s, radiopharmacists, chemists, physicists, engineers and technologists. The approved nuclear medicine department’s policy plan for the next five years of the division explicitly includes expansion of clinical/innovative applications of the NeuroExplorer, radiotheranostics and PET/RNT radiotracer production.